Camrelizumab, a fully humanized monoclonal antibody against PD-1,has been approved in the treatment of advanced esophageal squamous carcinoma in China.The purpose of this study was to observe the efficacy and safety of Camrelizumab in the treatment of esophageal cancer in the real world.
This is an open-label,prospective,multicenter, observational study. Eligible patients (pts) who received camrelizumab had esophageal cancer; age≥18, ECOG PS of 0-2; and measurable disease.
From August 1, 2019 to May 1, 2020. 100 pts were enrolled. There are 80 (80.0%) males. The median age was 65.0 yrs. The majority pts were at stage IV 74(74.0%), had prior surgery 47(47.0%) and radiotherapy 61(61.0%). Pts with ECOG PS 1-2 were 85 (85.0%). Metastases were detected in 88 (88.0%) pts, which mainly were lymphatic metastasis.Pts received first-line treatment, second-line, third-line or above, respectively were 20.0%, 31.0%, 48.0%. Before immunotherapy, only one patient was tested for PD-L1. Pts received apatinib monotherapy or in combination with chemotherapy or antiangiogenictherapy,respectively were 9.0%, 39.0%, 36.0%. There were 49 patients eligible for efficacy evaluation .9 achieved partial response, 30 had stable disease and 10 got progressive disease. Thus, the objective response rate (ORR) and disease control rate (DCR) were 18.4% and 79.6%. The incidence of AEs was 55 (55.0%) and the grade 3/4 treatment-related AEs was 3 (3.0) %. Main AEs were RCCEP (18.0%), and fatigue (17.0%), anorexia (11.0%). The grade 3/4 treatment-related AEs were RCCEP (1.0%), hypothyroidism (1.0%) and anemia(1.0%).
In real clinical applications, Camrelizumab is mostly used in patients with poor physical condition, metastatic and late stage, and most patients had front-line treatment.PD-L-1 detection is rarely performed in patients before medication, and most patients are treated with combination therapy of Camrelizumab.Camrelizumab is confirmed to be effective and safe in patients with esophageal cancer.Further analysis is needed to determine which factors are the positive factors in the treatment of Camrelizumab.
The authors.
Has not received any funding.
All authors have declared no conflicts of interest.